Abstract
Background: Transcriptome analyses have revealed the presence of numerous long non-coding RNAs (lncRNAs) in mammalian cells. Many lncRNAs are expressed in development-, differentiation-, and disease-specific manners, suggesting their importance as cell regulators. Some nuclear lncRNAs are bound to specific genomic loci, either near or distant from their own transcription sites, and regulate gene expression in cis or trans. These lncRNAs recruit epigenetic factors, including the DNA methyl transferase and histone modification complex, and mediate both the 3D genome structure and nuclear domains. LncRNAs are now considered as an emerging member of epigenetic regulators. LncRNAs are dysregulated in various types of cancer and act as either oncogenic or tumor- suppressing factors. They are involved in virtually all of the cancer hallmarks and are potential diagnostic markers and therapeutic targets.
Objective: In this review, we describe several representative lncRNAs and provide a current overview of the mechanisms by which lncRNAs participate in epigenetic regulation and contribute to cancer development.
Keywords: Long non-coding RNA, epigenetics, cancer, histone modification, DNA methylation, ELEANORS, chromatin.
Current Medicinal Chemistry
Title:Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Volume: 28 Issue: 25
Author(s): Hiroaki Tachiwana and Noriko Saitoh*
Affiliation:
- Division of Cancer Biology, The Cancer Institute of JFCR, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550,Japan
Keywords: Long non-coding RNA, epigenetics, cancer, histone modification, DNA methylation, ELEANORS, chromatin.
Abstract:
Background: Transcriptome analyses have revealed the presence of numerous long non-coding RNAs (lncRNAs) in mammalian cells. Many lncRNAs are expressed in development-, differentiation-, and disease-specific manners, suggesting their importance as cell regulators. Some nuclear lncRNAs are bound to specific genomic loci, either near or distant from their own transcription sites, and regulate gene expression in cis or trans. These lncRNAs recruit epigenetic factors, including the DNA methyl transferase and histone modification complex, and mediate both the 3D genome structure and nuclear domains. LncRNAs are now considered as an emerging member of epigenetic regulators. LncRNAs are dysregulated in various types of cancer and act as either oncogenic or tumor- suppressing factors. They are involved in virtually all of the cancer hallmarks and are potential diagnostic markers and therapeutic targets.
Objective: In this review, we describe several representative lncRNAs and provide a current overview of the mechanisms by which lncRNAs participate in epigenetic regulation and contribute to cancer development.
Export Options
About this article
Cite this article as:
Tachiwana Hiroaki and Saitoh Noriko *, Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer, Current Medicinal Chemistry 2021; 28 (25) . https://dx.doi.org/10.2174/0929867328666210215114506
DOI https://dx.doi.org/10.2174/0929867328666210215114506 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tip60: Main Functions and Its Inhibitors
Mini-Reviews in Medicinal Chemistry Extra Virgin Olive Oils Polyphenols: Biological Activities
Current Pharmaceutical Design Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario
Current Topics in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis
Current Drug Targets New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Current Cancer Therapy Reviews The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Current Pharmaceutical Biotechnology Nutritional Modulation of Terminal End Buds: Its Relevance to Breast Cancer Prevention
Current Cancer Drug Targets Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Induction of Quinone Reductase NQO1 by Resveratrol in Human K562 Cells Involves the Antioxidant Response Element ARE and is Accompanied by Nuclear Translocation of Transcription Factor Nrf2
Medicinal Chemistry Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics
Current Respiratory Medicine Reviews CSPG4 in Cancer: Multiple Roles
Current Molecular Medicine Disordered Interactome of Human Papillomavirus
Current Pharmaceutical Design Approaches to Gastrointestinal Cytoprotection: From Isolated Cells, Via Animal Experiments to Healthy Human Subjects and Patients with Different Gastrointestinal Disorders
Current Pharmaceutical Design Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry